Bios Life
This company leverages digital twin technology to create advanced predictive models for cancer screening and diagnostic analysis.
Overview
Bios Life is a health-tech venture focused on the application of digital twin simulations to improve early detection and clinical outcomes in oncology. By building virtual models of biological systems, the company enables personalized risk assessments and diagnostic screening, aiming to transform how cancer is identified and monitored within clinical environments. The organization recently emerged from stealth mode, securing $25 million in funding to accelerate its research and development. The capital injection is directed toward refining its simulation software and expanding its reach within the healthcare diagnostic market.
Funding History
Bios Life emerges from stealth with $25M to build digital twins for cancer screening
Frequently Asked Questions
- How much funding does AI Funding track for Bios Life?
- AI Funding tracks $25M for Bios Life across 1 funding round in this database.
- What does Bios Life do?
- Bios Life is a health-tech venture focused on the application of digital twin simulations to improve early detection and clinical outcomes in oncology. By building virtual models of biological systems, the company enables personalized risk assessments and diagnostic screening, aiming to transform how cancer is identified and monitored within clinical environments. The organization recently emerged from stealth mode, securing $25 million in funding to accelerate its research and development. The capital injection is directed toward refining its simulation software and expanding its reach within the healthcare diagnostic market.
- Where is Bios Life headquartered?
- Bios Life is headquartered in San Francisco, CA.
Related Insights
A data-driven analysis of AI funding across all 17 sectors — from Foundation Models to AI Healthcare — with sector totals, deal counts, top companies, and investment trends for 2026.
A comprehensive, data-driven analysis of AI venture funding in Q1 2026. $25.9 billion raised across 94 deals, with 14 mega-rounds capturing 79.8% of total capital. Europe breaks out with $6.65B, and billion-dollar seed rounds arrive for the first time.
A deep comparison of Science Corp.'s neurotech-driven brain-computer interfaces and Nscale's AI cloud infrastructure, examining how $230M and $2B in recent funding fuel fundamentally different visions of artificial intelligence.